Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom improvements but do not address anemia, a negative prognostic factor. Momelotinib, an inhibitor of ACVR1/ALK2, JAK1 and JAK2, demonstrated activity against anemia, symptoms, and splenomegaly in the phase 3 SIMPLIFY...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesa, Ruben, Harrison, Claire, Oh, Stephen T., Gerds, Aaron T., Gupta, Vikas, Catalano, John, Cervantes, Francisco, Devos, Timothy, Hus, Marek, Kiladjian, Jean-Jacques, Lech-Maranda, Ewa, McLornan, Donal, Vannucchi, Alessandro M., Platzbecker, Uwe, Huang, Mei, Strouse, Bryan, Klencke, Barbara, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417985/
https://www.ncbi.nlm.nih.gov/pubmed/35869266
http://dx.doi.org/10.1038/s41375-022-01637-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417985/
https://www.ncbi.nlm.nih.gov/pubmed/35869266
http://dx.doi.org/10.1038/s41375-022-01637-7

Ejemplares similares